Aug 14, 2019

Medtronic Partners With Capital District Physicians’ Health Plan, Inc. (CDPHP) on Outcomes-based Agreement to Increase Quality and Improve Access to Critical Diabetes Care

Strategic Partnership Marks First Agreement in New York to Incorporate Patient Engagement Program Aimed at Improving Diabetes Management

DUBLIN – August 14, 2019 – Medtronic plc (NYSE:MDT), the global leader in medical technology, and Capital District Physicians' Health Plan, Inc. (CDPHP) today announced an innovative...

DUBLIN – August 14, 2019 – Medtronic plc (NYSE:MDT), the global leader in medical technology, and Capital District Physicians' Health Plan, Inc.  (CDPHP) today announced an innovative outcomes-based agreement for individuals  with type 1 and type 2 diabetes that utilize a Medtronic insulin pump. Under the  strategic partnership, Medtronic will provide eligible CDPHP members access to state-of-the-art  technologies, supplies, and education and training support services to manage their  diabetes. Additionally, a component of Medtronic's reimbursement will be tied to  successfully meeting agreed upon clinical improvement thresholds for enrolled  members – such as A1C reduction, increased Time in Range, and reduced  hypoglycemic events.

The agreement also provides an  opportunity for CDPHP members to proactively engage in their diabetes  management through a patient engagement program, known as Medtronic Inner  CircleSM. The program from Medtronic uses gamification - the  application of game design elements - to motivate and encourage people living  with diabetes to achieve better health outcomes. Participants will have the  ability to earn points by completing certain activities or achieving monthly  goals for spending more time in the clinically recommended glycemic range of  70-180 mg/dL.

"We are incredibly excited to offer CDPHP  members access to our unique technology solutions that use predictive analytics,  as well as the opportunity to participate in our Inner Circle program, to more  effectively manage their diabetes," said Suzanne Winter, vice president of the  Americas region for the Diabetes Group at Medtronic. "Our ultimate goal is to  elevate the patient experience, improve clinical outcomes and provide unmatched  support to health plan members."

"Today, nearly 10 percent of U.S. adults  are living with diabetes, and another 30 percent are estimated to have  prediabetes. The rising cost and prevalence of the disease is putting a major  strain on health systems and patients nationwide, including right here in  Albany, NY," said CDPHP President and CEO, Dr. John D. Bennett. "This  partnership focuses on delivering patient-centered solutions to improve  outcomes while reducing soaring health care costs," added Bennett.

Gerard Barr  of Cohoes, NY is a CDPHP member living with type 1 diabetes who recently  started wearing the MiniMed™ 670G system under this new partnership.

"This time  last year my diabetes felt out of control and I lost my job as a school bus driver,"  said Barr. "Today, I've improved my A1C and I'm on my way to a healthier  lifestyle. 1 Not only do I feel better, but I started driving  again."

In addition to improving the quality of  care for CDPHP members, this partnership has the potential to improve patient  engagement in doctor's offices, including Ellis Medicine's Endocrine Care Team.

"We have had success transitioning a  number of individuals living with diabetes in our practice to the MiniMed 670G  system. This is amazing!" said Dawn Dluge-Aungst, RPA-C, CDE, Physician  Assistant, at the Ellis Medicine Endocrine Care Team.

The four-year partnership between CDPHP  and Medtronic provides eligible members access to insulin pumps with  SmartGuard™ technology, including the MiniMed 670G  system — the first hybrid closed loop system in the world and the only system  that automates and personalizes the delivery of basal insulin 24 hours a day  to keep patients' blood glucose levels in range based on their  personalized needs. See animation to understand how the MiniMed 670G  system works.

About the  Diabetes Group at Medtronic (
  Medtronic is working  together with the global community to change the way people manage diabetes.  The company aims to transform diabetes care by expanding access, integrating  care, and improving outcomes, so people living with diabetes can enjoy greater  freedom and better health.

About Medtronic
  Medtronic plc (, headquartered in  Dublin, Ireland, is among the world's largest medical technology, services and  solutions companies - alleviating pain, restoring health and extending life for  millions of people around the world. Medtronic employs more than 90,000 people  worldwide, serving physicians, hospitals and patients in more than 150  countries. The company is focused on collaborating with stakeholders around the  world to take healthcare Further, Together.

  Established in 1984,  CDPHP is a physician-founded, member-focused and community-based not-for-profit  health plan that offers high-quality affordable health insurance plans to  members in 26 counties throughout New York. CDPHP is also on FacebookTwitterLinkedIn, and Instagram.

Any forward-looking statements are  subject to risks and uncertainties such as those described in Medtronic's  periodic reports on file with the Securities and Exchange Commission. Actual  results may differ materially from anticipated results.


1 Individual results may vary.


Kendra Cassillo
Medtronic Public Relations

Ryan Weispfenning
Medtronic Investor Relations

Ali Skinner
CDPHP Public Relations